Combined preparation and application of combined preparation in preparing non-small-cell lung carcinoma drug
File(s)Erlotinib + EA CN103330940A.pdf (691.78 KB)
Published version
Author(s)
Tang, H
Li, H
Wang, Y
Pardo, OE
Seckl, MJ
Type
Patent
Abstract
The invention discloses a combined preparation and an application of the combined preparation in preparing a non-small-cell lung carcinoma drug. An EGFR (Epidermal Growth Factor Receptor) tyrosine kinase inhibitor and a preparation for increasing a concentration of glutathione (GSH) in lung carcinoma cells are administered simultaneously or successively. According to the combined preparation and the application, through a systemic research, the GSH plays an important role in resisting the EGFR tyrosine kinase inhibitor to an EGFR T790M mutation non-small-cell lung carcinoma, so that drug resisting cells are sensitive to treatment of the EGFR tyrosine kinase inhibitor again by utilizing a mode of increasing the concentration of the GSH in the lung carcinoma cells; and a cell experiment and an animal experiment prove that the method is safe and effective, can effectively kill the lung carcinoma cells, and can inhibit proliferation of the lung carcinoma cells.
Date Issued
2013-10-02
Citation
2013
Sponsor
Commission of the European Communities
Identifier
Patent number: CN103330940A
Grant Number
259770
Publication Status
Published
Article Number
CN201310291126.4